Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ANIP | US
0.77
1.04%
Healthcare
Biotechnology
30/06/2024
09/03/2026
74.81
73.83
74.97
72.64
ANI Pharmaceuticals Inc. a biopharmaceutical company develops manufactures and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances oncology products hormones and steroids injectables and other formulations including extended release and combination products. The company manufactures oral solid dose products; semi-solids liquids and topicals; and potent products as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains wholesalers distributors and mail order pharmacies and group purchasing organizations. ANI Pharmaceuticals Inc. was incorporated in 2001 and is headquartered in Baudette Minnesota.
View LessLow Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
Price Below SMA10D
Smallcap (300M - 2B USD)
Weak Operating Margin (< 10%)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
34.1%1 month
31.6%3 months
36.2%6 months
30.8%50.68
9.89
2.78
0.68
0.34
11.41
2.47
1.06
107.97M
1.57B
1.57B
-
6.54
1.38K
18.40
5.90
5.11
14.01
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
5.72
Range1M
9.62
Range3M
14.64
Rel. volume
0.67
Price X volume
17.67M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Zymeworks Inc | ZYME | Biotechnology | 24.25 | 1.72B | 0.71% | n/a | 4.94% |
| Novavax Inc | NVAX | Biotechnology | 10.55 | 1.69B | 5.71% | n/a | -54.03% |
| Sarepta Therapeutics Inc | SRPT | Biotechnology | 17.64 | 1.68B | 5.57% | 169.44 | 127.19% |
| Vericel Corporation | VCEL | Biotechnology | 34.12 | 1.67B | 1.22% | 4.17K | 39.42% |
| Immunocore Holdings plc | IMCR | Biotechnology | 33.41 | 1.67B | 1.43% | n/a | 131.69% |
| Relay Therapeutics Inc. | RLAY | Biotechnology | 10.14 | 1.65B | 2.53% | n/a | 7.50% |
| Iovance Biotherapeutics Inc | IOVA | Biotechnology | 5.41 | 1.64B | 5.46% | n/a | 10.63% |
| Harmony Biosciences Holdings Inc. | HRMY | Biotechnology | 28.57 | 1.62B | 0.85% | 18.16 | 40.71% |
| Agios Pharmaceuticals Inc | AGIO | Biotechnology | 28.53 | 1.62B | 3.86% | n/a | 9.78% |
| Seres Therapeutics Inc | MCRB | Biotechnology | 9.32 | 1.59B | 2.08% | n/a | -244.19% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 14.07 | 1.41B | 1.22% | n/a | 19.46% |
| Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 36.22 | 1.14B | 1.06% | 51.60 | 88.92% |
| Winnebago Industries Inc | WGO | Recreational Vehicles | 35.25 | 1.02B | -2.87% | 22.53 | 56.33% |
| Janus International Group Inc. | JBI | Building Products & Equipment | 5.39 | 783.29M | 1.89% | 11.62 | 116.21% |
| Latham Group Inc. | SWIM | Building Products & Equipment | 6.31 | 729.29M | 0.16% | 65.18 | 77.00% |
| Fox Factory Holding Corp | FOXF | Recreational Vehicles | 16.37 | 682.35M | 0.37% | 42.05 | 64.69% |
| Ennis Inc | EBF | Building Products & Equipment | 21.16 | 550.24M | -0.70% | 13.28 | 2.28% |
| Malibu Boats Inc | MBUU | Recreational Vehicles | 25.67 | 513.16M | -0.39% | n/a | 1.50% |
| ACCO Brands Corporation | ACCO | Building Products & Equipment | 3.67 | 351.58M | -6.14% | n/a | 174.23% |
| Camping World Holdings Inc | CWH | Recreational Vehicles | 7.47 | 337.11M | 1.49% | n/a | 3644.76% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 11.41 | 0.53 | Expensive |
| Ent. to Revenue | 2.47 | 3,967.00 | Cheaper |
| PE Ratio | 50.68 | 41.03 | Expensive |
| Price to Book | 2.78 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 36.20 | 72.80 | Lower Risk |
| Debt to Equity | 0.68 | -1.23 | Expensive |
| Debt to Assets | 0.34 | 0.25 | Expensive |
| Market Cap | 1.57B | 3.66B | Emerging |